Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Interest Expenses (2022 - 2025)

Tarsus Pharmaceuticals (TARS) has 4 years of Interest Expenses data on record, last reported at $2.2 million in Q4 2025.

  • For Q4 2025, Interest Expenses fell 4.24% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $8.9 million, up 13.84%, while the annual FY2025 figure was $8.9 million, 13.84% up from the prior year.
  • Interest Expenses reached $2.2 million in Q4 2025 per TARS's latest filing, down from $2.3 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.4 million in Q3 2024 and bottomed at $316000.0 in Q1 2022.
  • Average Interest Expenses over 4 years is $1.4 million, with a median of $986000.0 recorded in 2023.
  • Peak YoY movement for Interest Expenses: surged 184.97% in 2024, then decreased 7.24% in 2025.
  • A 4-year view of Interest Expenses shows it stood at $692000.0 in 2022, then surged by 42.92% to $989000.0 in 2023, then soared by 133.77% to $2.3 million in 2024, then fell by 4.24% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $2.2 million in Q4 2025, $2.3 million in Q3 2025, and $2.2 million in Q2 2025.